Search all trials

Find therapies in clinical trials near you – page 2

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Coeliac disease

Recruiting

Investigational

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational

Finland

Participants:18–64 years · 65+ years
Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate

Contact Research Centre

Neoplasm malignant

Recruiting

Registered drugNo placebo

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Favezelimab

Contact Research Centre

Influenza+1

Recruiting

Registered drugNo placebo

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo

Finland

Participants:65+ years · Healthy volunteers
Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED

Contact Research Centre

Gastrointestinal stromal tumour

Recruiting

InvestigationalNo placebo

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Imatinib Mesilate

Contact Research Centre

Non-Hodgkin's lymphoma

Recruiting

InvestigationalNo placebo

Phase 1/2 Study Evaluating Safety and Activity of GSK5926371 in Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

InvestigationalNo placebo

Finland

Participants:18–64 years · 65+ years

Contact Research Centre

Osteosarcoma

Recruiting

Registered drugNo placebo

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo

Finland

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cabozantinib

Contact Research Centre

Interstitial lung disease

Recruiting

Investigational

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Investigational

Finland

Participants:0–17 years
Substances:Bi 1015550

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Investigational

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational

Finland

Participants:18–64 years · 65+ years
Substances:LUNSEKIMIG

Contact Research Centre

Ovarian cancer recurrent

Recruiting

Registered drugNo placebo

Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Registered drug

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

Finland

Participants:18–64 years · 65+ years
Substances:Calcium Folinate

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Registered drugNo placebo

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Neuroendocrine carcinoma

Recruiting

Registered drugNo placebo

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Find therapies in clinical trials near you – page 2

273 trials match your criteria

Coeliac disease

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Neoplasm malignant

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Influenza+1

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Gastrointestinal stromal tumour

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

Non-Hodgkin's lymphoma

Phase 1/2 Study Evaluating Safety and Activity of GSK5926371 in Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Osteosarcoma

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Interstitial lung disease

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Chronic obstructive pulmonary disease

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Ovarian cancer recurrent

Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Pancreatic carcinoma metastatic

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Non-small cell lung cancer+1

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Neuroendocrine carcinoma

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.